Only to be administered by appropriately trained healthcare professionals who are qualified or accredited in accordance with national law.

Pack description

This pack contains one prefilled syringe of 1.0 ml sterile viscoelastic implant with an aesthetic purpose and two 30G x ½˝ disposable sterile needles to be attached to the syringe for injection, co-packaged within one blister. Besides the blister, each box contains three patient record labels, instructions for use healthcare professionals including the international implant card and a Link to the patient information leaflet. The blister containing the syringe and needles has not been sterilized. For correct assembly of the syringe and needle, please refer to the pictures ❶ to ❻. Information on the folding box refers to the pack

Viscoelastic implant – instructions for use

Technical description: The device is a sterile, absorbable, biodegradable, viscoelastic, clear, transparent, isotonic, and homogenised injectable gel implant used as a soft tissue filler without an intended medical purpose. It is intended for single use, is non-active, and without measuring function. It is steam sterilized in the syringe representing the sterile barrier. No animal or human tissues or cells or their derivates are used during manufacturing or as raw materials. The viscoelastic implant is stored in a prefilled syringe. The intended use of the prefilled syringe is to serve as the sterile barrier system for the viscoelastic implant. The syringe (in combination with a hypodermic needle) is intended to serve as the delivery system for the viscoelastic implant.

Composition: The viscoelastic implant consists of non-crosslinked hyaluronic acid (present as sodium hyaluronate), obtained from *Streptococcus equi* bacteria, as well as glycerol, and is phosphate-citrate buffered at a pH of 6.8–7.6. It contains 1.80 % sodium hyaluronate, 2.12 % glycerol, 0.13 % disodium phosphate dodecahydrate and 0.01 % citric acid dissolved in water for injection. The average molecular weight for the hyaluronic acid raw material is 3.2–3.5 x 10^6 Dalton (calculated from intrinsic viscosity).

Indications: The viscoelastic implant is indicated to maintain hydration, to improve tone and elasticity of the skin and, thereby, correct fine lines on the face, including lateral canthal lines (also called "crow's feet") and perioral rhytids (also called "smile lines" or "smoker's lines"). It is indicated to be injected into the superficial dermal tissue.

Intended purpose: The intended aesthetic purpose of the viscoelastic implant is to replenish the loss of hyaluronic acid.

Intended consumer: The intended consumers are adults 18 years of age or older requesting aesthetic hyaluronic acid filler treatments.

Intended user: The intended user is an appropriately trained healthcare professional who is qualified or accredited in accordance with national law. The viscoelastic implant is not intended to be used by lay persons.

Contraindications: The viscoelastic implant must not be used in:
- consumers who tend to develop hypertrophic scars, have pigment disorders or have a susceptibility to keloid formation as the treatment may trigger these complications. | - consumers who are known to be hypersensitive to components of the device or gram-positive bacterial proteins as the treatment may trigger allergic reactions of different grades of severity. | - pregnant or breast-feeding women. | - individuals younger than 18 years of age.

Warnings: As long as the syringe is stored in its originally sealed blister, the viscoelastic implant inside the intact syringe is guaranteed to be sterile until the use-by date printed on the folding box and the label on the syringe. A compromised sterile barrier may lead to a non-sterile implant that could cause bacterial infections associated with skin inflammation and irritation, erythema, pain, fever and abscess. Therefore do not use the syringe beyond the use-by date or if it is cracked or broken. Do not use a syringe with an open or shifted tip cap, a loose Luer-Lock adapter or from an opened or damaged blister. Do not transfer the viscoelastic implant to another application device as this may cause contamination. Do not re-use the syringe or needle as it creates a potential infection risk for consumers or users. Do not use any other needle than included in the pack and do not manipulate/bend the needle. Avoid injection into blood vessels and nerves.
The implanted viscoelastic gel is safe in a magnetic resonance environment. The delivery system is potentially infectious after use and must be discarded in a sharps disposal container.

Precautions for use: Avoid areas presenting cutaneous, inflammatory and/or infectious processes (e.g. acne, herpes) as this may lead to the proliferation of infection or an aggravation of the present condition. Avoid injecting into tendons, ligaments or muscles as this may cause pain and interferes with known performance and safety of the device. Avoid using the viscoelastic implant in association with laser therapy, chemical peeling, dermabrasion or other substances for mesotherapy as this may cause skin inflammation/irritation and interferes with known performance and safety of the device. There are no available clinical data (efficacy, tolerance) about injecting the viscoelastic implant into an area which has already been treated with any filling product or botulinum toxin. Avoid injecting in an area that has been previously treated with permanent fillers as this could potentially aggravate latent adverse events or interfere with the aesthetic outcome of the treatment. Avoid bacterial infection of the treatment area and impaired wound healing by keeping it clean and washing your hands before touching the area in the first 48 hours. To avoid additional stress to the skin, consumers should be advised not to apply any make-up for 12 hours after the injection and to avoid strenuous exercise and exposure to extensive sun or heat in the first 48 hours. There are incompatibilities between sodium hyaluronate and quaternary ammonium compounds such as benzalkonium chloride solutions. Therefore, the viscoelastic implant should never be put in contact with these substances or with medical-surgical instruments that have been in contact with these substances.

Limitations: Consumers on anticoagulant therapy or consumers receiving platelet aggregation inhibitors (e.g. acetylsalicylic acid) should not be treated with this viscoelastic implant without consulting their physician beforehand. For consumers with a history of autoimmune or connective tissue disease and/or who are receiving immune (-modulation) therapy, or with a history of severe allergies or anaphylactic shock, treatment decisions need to be taken on a case-to-case basis. For consumers presenting with an active or evolving autoimmune disease, the treatment is not recommended. There are no clinical data on the use of the product in male consumers as well as consumers under the age of 28 and above the age of 77.

Undesired side effects: Users must inform the consumers that there are potential side effects and/or incompatibilities associated with the implantation of this viscoelastic implant, which may occur immediately or may be delayed. They are generally mild and transient in nature, but may last for a few days. It is, therefore, important to take these possible complications into account before initiating the treatment.
Undesired side effects observed at the injection site during the clinical study: haematoma, herpes simplex reactivation, swelling/oedema.
Additional undesired side effects were observed after introduction to market: bacterial infection, granuloma, haemorrhage/bleeding (incl. ecchymosis), hypersensitivity/allergic reaction, pain, skin discolouration (incl. erythema), itching sensation, skin inflammation/irritation, subcutaneous nodules.
The following undesired side effects have been observed with similar viscoelastic implants and are considered as potential risks for this device: bruise/contusion, medical device site induration, Tyndall effect. Consumers must be told to seek medical advice as soon as any undesired side effects occur. The physician should treat these side effects appropriately.
The following is a selective list of treatment options for some of the most common side effects in the context of hyaluronic acid dermal fillers (please refer to specialised guidance documents for detailed information): Bleeding, haematoma, senoma may be prevented or decreased by applying a manual or cold compress, and applying a compressive bandage. As adjuncts arnica cream or gel and topical Vitamin K may be used. Reactive swelling and oedema may be prevented or decreased by applying a manual or cold compress, oral antihistamines or oral corticosteroids. For abscesses and bacterial infections (incl. fever), medical treatment, including appropriate antibiotic therapy, must be initiated by a physician. Non-inflammatory nodules are generally caused by an abundance of product (overdosing); local steroids or 5-fluorouracil injections are not recommended. Surgical excision may be offered, or one may elect to camouflage the asymmetries until the substance is metabolised. For late or delayed onset inflammatory reaction, including infections and granulomas, antibiotic therapy or surgical excision may be offered. Allergic reactions and hypersensitivity to hyaluronic acid are in general rare and self-limiting and resolve with supportive measures within a few hours or days. Severe allergic reactions with immediate substantial swelling, angioedema, airway obstruction, and anaphylactic shock may occur, but are very rare. It is, therefore, recommended to have an epinephrine pen to hand during procedures in case of emergencies. Mast-cell mediated allergic reactions may respond to oral antihistamines. Delayed hypersensitivity (days to weeks post injection) usually resolves without untoward consequences but may be treated with oral or local steroids depending on the severity of the reaction. The allergen should be removed if possible.
Please report undesired side effects and serious incidents to the manufacturer through complaint@croma.at or refer to the contact information. Please also report any serious incident related to the use of this device to the competent authority of the member state in which the user and/or consumer is established.

Instructions for good administering practice of the viscoelastic implant: In order to minimise the risks of potential complications, this viscoelastic implant should only be used by appropriately trained healthcare professionals who are qualified or accredited in accordance with national law. Good clinical practice guidelines need to be adhered to and treatment carried out in the healthcare professional's office or other medical environment.
Please use appropriate personal protective equipment. The skin should be thoroughly cleaned, degreased and disinfected prior to injection of the viscoelastic implant and an appropriate aseptic technique should be employed throughout the procedure. There are no specifically recommended topical antiseptics, but chlorhexidine, chloroxylenol, iodophors, alcohol, and iodine are considered appropriate. The viscoelastic implant must only be injected into non-inflamed, healthy skin. It must be injected into the superficial dermal tissue. The following injection techniques were used successfully during the clinical investigation of this viscoelastic implant, the choice of technique depending on user preference: multipuncture technique (mesotherapy). Linear threading, retrograde technique and cross-hatching have also been applied successfully with this device and similar viscoelastic implants. Use the sterile 30G x ½˝ needle which is packaged with the syringe and slowly inject with the least amount of pressure necessary. The insertion of the needle may lead to superficial needle stick/puncture wounds. If the needle is blocked, do not increase the pressure on the plunger rod, but stop the injection and replace the needle. Inject low volumes in two or more sessions instead of high volumes in one session. The amount injected will depend on the skin's condition, where the initial injection at Week 0 may be supplemented with one or two additional injections with a three-week interval between injections (i.e. at Weeks 3 and 6 after the initial injection at Week 0). The scale on the syringe serves as an orientation for the user. The maximum applied dosage per treatment and per consumer substantiated by clinical data is up to 6.0 ml for the treatment of perioral rhytids and up to 3.3 ml for the bilateral treatment of lateral canthal lines (1.7 ml left side plus 1.6 ml right side). After the injection, healthcare professionals may perform a light massage in order to distribute the viscoelastic implant uniformly. The consumer should be asked to remain on site for 30 minutes after the injection to detect signs of hypersensitivity. There is no need for a mandatory follow-up.

Device performance: During the clinical investigation CPH-401-201364, subjects received up to three injections per treatment over the course of 6 weeks (i.e. at Weeks 0, 3 and 6). At 2 weeks after the last injection at Week 6 (i.e. Week 8 after the initial injection at Week 0; primary endpoint), 100 % of subjects showed aesthetic improvement based on the investigator-assessed Global Aesthetic Improvement Scale (GAIS). This effect was maintained in 80.7 % of subjects up to 10 weeks after the last injection (i.e. Week 16 after the initial injection at Week 0) and in 53.8 % of subjects up to 18 weeks after the last injection (i.e. Week 24 after the initial injection at Week 0). Skin attributes such as tone and elasticity were significantly improved while hydration was maintained. Improvement in skin tone (firmness) reached its peak effect from baseline at 2 weeks after the last injection (i.e. at Week 8 after the initial injection at Week 0). Improvement of skin elasticity reached its peak effect from baseline at 6 weeks after the last injection (i.e. at Week 12 after the initial injection at Week 0).
Subject satisfaction was also very high in the study, with more than 70 % of subjects being 'satisfied' or 'very satisfied' up to 30 Weeks after the last injection (i.e. Week 36 after the initial injection at Week 0).
The aesthetic effect after initial injection of the viscoelastic implant lasts up to 16 weeks for lateral canthal lines and up to 24 weeks for perioral rhytids. Skin tone and elasticity were significantly improved at 8 (tone) and 12 weeks (elasticity) after the initial injection of the viscoelastic implant. Up to 2 additional injections after the initial injection may be placed at a previously injected location with a 3-week interval between injections. Based on the available data, the lifetime of the viscoelastic implant is determined to be 2 weeks.

International implant card and patient information leaflet: For Patient Information Leaflet please see www.cromapharma.com/productinformation/australia/croma-revitalis and inform the consumer before treatment. The international implant card is part of this information for use and must be handed out to the consumer to allow traceability. Three adhesive patient record labels are enclosed in the box. One of these labels must be detached and affixed to the field "PATIENT RECORD LABEL" on the implant card. The healthcare professional must fill in the following information: - name of the consumer or consumer identification | - date of implantation | - name and address of the healthcare institution which performed the implantation | - location, number and volume of the injections (please use the facial outline on the implant card to record this information).
In case the information on the patient record label is not legible or the labels are missing, please copy the UDI-DI and LOT number from the label on the syringe. In case you use more than one syringe during the course of a treatment session, please provide the consumer with a separate implant card for each syringe.

Storage: The device should be stored in the original blister and folding box at 2–25 °C / 36–77 °F, in a dry place and protected from sunlight, heat and frost. Do not use the device if it has been stored outside of these conditions since proper functionality can only be guaranteed if stored correctly. The syringe is made of glass, handle with care (risk of laceration when broken).

K-Pack II Needle 30G x ½˝ (0.3 x 12 mm) TW
For further information on the safety and performance of the needles in this pack please see safetyinfo.terumo-europe.com

Instructions for the correct assembly of syringe and needle:
Hold the Luer-Lock adapter as shown in ❶
To remove the tip cap, twist ❷ and pull carefully ❸



Following the instructions above will prevent the trapping of air bubbles
Hold the syringe as shown in ❹
Open the enclosed needle container and insert the needle firmly ❺



Holding the Luer-Lock, tightly secure the needle by twisting it clockwise ❻



Applied harmonized standards and Regulations:
Commission Implementing Regulation (EU) 2022/2346 Annex I and Annex IV,
Fully applied standards: EN ISO 13485:2016+A11:2021
EN ISO 14971:2019+A11:2021
Applicable parts applied: EN ISO 10993-9:2021
EN ISO 10993-10:2023
EN ISO 10993-12:2021
EN ISO 10993-17:2009
EN ISO 10993-18:2020
EN ISO 10993-23:2021
EN ISO 11607-1:2020
EN ISO 11737-1:2018
EN ISO 15223-1:2021

Explanation of international symbols:

31	Date of implantation
	Patient identification
	Health care centre or doctor
	Patient information website
UDI	Unique device identifier
LOT	Lot number
MD	Medical device
	Manufacturer
VISCOELASTIC IMPLANT	Viscoelastic implant
18+	Adults 18 years of age or older
	Caution
	Consult instructions for use
	Keep dry
2°C 25°C	Temperature limit
	Keep away from sunlight
	Fragile, handle with care
	Do not use if package is damaged and consult instructions for use
	Do not re-use
	Do not resterilize
REF	Reference number
SN	Serial number
	Use by
	Date of manufacture
PROCEDURE PACK PRODUCER	Procedure pack producer
PREFILLED SYRINGE	Prefilled syringe for single use
NEEDLE	Sterile needle for single use
	Single sterile barrier system with protective packaging outside
	Single sterile barrier system
STERILE	Sterilized using steam
STERILE EO	Sterilized using ethylene oxide
	Non-pyrogenic



croma
revitalis

croma revitalis

1 x 1,0 ml PREFILLED SYRINGE PROCEDURE PACK PRODUCER

CROMA-PHARMA GmbH
Industriezeile 6
2100 Leobendorf
Austria
www.cromapharma.com
CE 0123

2 x 30G x ½˝ NEEDLE

TERUMO Europe N.V.
Interleuvenlaan 40
3001 Leuven
Belgium
safetyinfo.terumo-europe.com
CE 0197

Australian Sponsor:
MDSS AU Pty Ltd
Ground Floor, Suite 5S
97-99 Bathurst Street
Sydney NSW 2000
Australia

22 PAP

Last revised: 2024-04